These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 18635756)

  • 61. Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
    Oyama J; Tanaka A; Sato Y; Tomiyama H; Sata M; Ishizu T; Taguchi I; Kuroyanagi T; Teragawa H; Ishizaka N; Kanzaki Y; Ohishi M; Eguchi K; Higashi Y; Yamada H; Maemura K; Ako J; Bando YK; Ueda S; Inoue T; Murohara T; Node K;
    Cardiovasc Diabetol; 2016 Jun; 15():87. PubMed ID: 27317093
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649.
    Dua P; Gurrell R; Kirby S; Sudworth M; Loudon PT
    Clin Rheumatol; 2016 Aug; 35(8):2045-2051. PubMed ID: 27094945
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
    Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
    Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
    Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
    Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Quantification of uric acid, xanthine and hypoxanthine in human serum by HPLC for pharmacodynamic studies.
    Cooper N; Khosravan R; Erdmann C; Fiene J; Lee JW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jun; 837(1-2):1-10. PubMed ID: 16631418
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.
    White WB; Chohan S; Dabholkar A; Hunt B; Jackson R
    Am Heart J; 2012 Jul; 164(1):14-20. PubMed ID: 22795277
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
    Schumacher HR
    Expert Opin Investig Drugs; 2005 Jul; 14(7):893-903. PubMed ID: 16022578
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline.
    Tsai M; Wu JT; Gunawardhana L; Naik H
    Int J Clin Pharmacol Ther; 2012 May; 50(5):331-7. PubMed ID: 22541837
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Xanthine oxidoreductase and its inhibitors: relevance for gout.
    Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
    Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose.
    Carroll MB; Smith DM; Shaak TL
    Rheumatol Int; 2017 Mar; 37(3):445-453. PubMed ID: 27798726
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Febuxostat for gout.
    Drug Ther Bull; 2010 Jul; 48(7):78-82. PubMed ID: 20631196
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy and Safety of Febuxostat in Kidney Transplant Patients.
    Baek CH; Kim H; Yang WS; Han DJ; Park SK
    Exp Clin Transplant; 2018 Aug; 16(4):401-406. PubMed ID: 29251581
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome.
    Sánchez-Lozada LG; Tapia E; Bautista-García P; Soto V; Avila-Casado C; Vega-Campos IP; Nakagawa T; Zhao L; Franco M; Johnson RJ
    Am J Physiol Renal Physiol; 2008 Apr; 294(4):F710-8. PubMed ID: 18216151
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of R1663, an oral factor Xa inhibitor, in healthy young subjects coupled with exploration of influence of gender and age.
    Schmitt C; Charoin-Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T
    Thromb Haemost; 2012 Jul; 108(1):54-64. PubMed ID: 22552265
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Gout therapeutics: new drugs for an old disease.
    Burns CM; Wortmann RL
    Lancet; 2011 Jan; 377(9760):165-77. PubMed ID: 20719377
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetic and pharmacodynamic properties of a novel xanthine oxidase inhibitor, BOF-4272, in healthy volunteers.
    Uematsu T; Nakashima M
    J Pharmacol Exp Ther; 1994 Aug; 270(2):453-9. PubMed ID: 8071837
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Renal function in gout: long-term treatment effects of febuxostat.
    Whelton A; Macdonald PA; Zhao L; Hunt B; Gunawardhana L
    J Clin Rheumatol; 2011 Jan; 17(1):7-13. PubMed ID: 21169856
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol.
    Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hada T
    J Rheumatol; 2001 Oct; 28(10):2294-7. PubMed ID: 11669172
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
    Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
    Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.